地榆升白片升高肺癌化疗患者白细胞效果评价及对生存质量的影响分析

Effect evaluation of Diyu Shengbai Tablet on elevating leukocytes in patients with lung cancer undergoing chemotherapy and its impact on quality of life

关键词:  地榆升白片  化疗  肺癌患者  白细胞  生存质量

Key words:  Diyu Shengbai Tablet  chemotherapy  lung cancer patient  leukocyte  quality of life

摘要:

[目的] 评估使用地榆升白片后肺癌化疗患者提升白细胞的效果，以及对其生活质量的影响。[方法] 选取2024年1—4月在天津市胸科医院接受治疗的126 例肺癌化疗患者进行研究，采用随机对照方法，将126 例肺癌化疗患者分为试验组和对照组，每组各63 例。试验组患者在治疗期间采用常规化疗加服地榆升白片，剂量为0.75 g/次，每日3 次，服用周期为4 周。对照组患者采用常规化疗。两组患者均接受其他常规治疗并给予营养支持。试验过程中每周复查血化验指标，记录白细胞水平的变化情况。比较两组患者白细胞值变化情况、中性粒细胞变化情况、骨髓抑制发生率及生存质量变化情况。[结果] 试验组患者加服地榆升白片后白细胞数量、中性粒细胞数量远高于对照组患者。经治疗后试验组患者骨髓抑制发生率明显低于对照组患者，差异有统计学意义（P<0.05）；试验组患者治疗有效率为95.24%，对照组患者为80.95%，两组差异有统计学意义（P<0.05）；试验组患者在生存质量5个维度综合评分（情感状况、生理状况、社交/家庭状况、功能状况、相关症状）均显著优于对照组，差异有统计学意义（P<0.05）。[结论] 地榆升白片可有效提高肺癌化疗患者的白细胞以及中性粒细胞数量，拮抗骨髓抑制作用，提升患者的生存质量。

Abstract:

[Objective] To evaluate the effect of Diyu Shengbai Tablets on improving leukocytes and quality of life in patients with lung cancer after chemotherapy. [Methods] The 126 lung cancer patients with chemotherapy treated in Tianjin Chest Hospital from January to April 2024 were selected for the study. Using a randomized controlled trial,126 patients with lung cancer chemotherapy were divided into trial group and control group,with 63 patients in each group. The trial group received Diyu Shengbai Tablet during conventional chemotherapy with 0.75 g a time,3 times a day for 4 weeks. Control patients were treated with conventional chemotherapy. Both two groups received other conventional treatments and received nutritional support. During the test,the blood test index was reviewed every week,and recorded the change of leukocyte level. The change of leukocyte values,neutrophils,incidence of myelosuppression and quality of life were compared between the two groups. [Results] The test group had significantly more leukocytes and neutrophils than those in the control group,with a statistically significant difference(P<0.05). After treatment,the incidence of myelosuppression was significantly lower than that in the control group,with a statistically significant difference(P<0.05). The total effective rate of the trial group was 95.24%,The control group's total effective rate was 80.95%. The difference between the two groups was statistically significant(P<0.05). The trial group patients showed significantly better comprehensive scores in five dimensions of quality of life(emotional,physiological,social/family,functional,and related symptoms) compared to the control group,with statistical significance(P<0.05). [Conclusion] Diyu Shengbai Tablet can effectively improve the number of leukocytes and neutrophils in patients with lung cancer undergoing chemotherapy,antagonize the side effects of bone marrow suppression,and improve the quality of life of patients.